Ireland

--:--IST

Latest

Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide

Subscribe

Registers› Irish medicines ›CSL Behring GmbH

Medicines register · Ireland

CSL Behring GmbH — licensed medicines

35 medicines held by CSL Behring GmbH on the Irish market, from the HPRA register.

Source: HPRA open dataset ("Authorised or Transfer Pending Products"), CC BY 4.0. Complete coverage — all 10,336 authorised products are in this register. Synced 20 Sep 2026, 17:51 UTC

Narrow the register Reset

Search within results

Matches brand name, active substance, licence holder and licence number.

Browse by first letter

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9

Medicine

Active substance

Licence holder

Status

AFSTYLA 1000 IU powder and solvent for solution for injection EU/1/16/1158/003

Lonoctocog alfa

CSL Behring GmbH

—

AFSTYLA 1500 IU powder and solvent for solution for injection EU/1/16/1158/004

Lonoctocog alfa

CSL Behring GmbH

—

AFSTYLA 2000 IU powder and solvent for solution for injection EU/1/16/1158/005

Lonoctocog alfa

CSL Behring GmbH

—

AFSTYLA 250 IU powder and solvent for solution for injection EU/1/16/1158/001

Lonoctocog alfa

CSL Behring GmbH

—

AFSTYLA 2500 IU powder and solvent for solution for injection EU/1/16/1158/006

Lonoctocog alfa

CSL Behring GmbH

—

AFSTYLA 3000 IU powder and solvent for solution for injection EU/1/16/1158/007

Lonoctocog alfa

CSL Behring GmbH

—

AFSTYLA 500 IU powder and solvent for solution for injection EU/1/16/1158/002

Lonoctocog alfa

CSL Behring GmbH

—

Alburex 20, 200 g/l, solution for infusion PA0800/008/002

Human albumin

CSL Behring GmbH

Not marketed

Alburex 5, 50 g/l, solution for infusion PA0800/008/001

Human albumin

CSL Behring GmbH

Not marketed

ANDEMBRY 200 mg solution for injection in pre-filled pen EU/1/24/1885/003-004

Garadacimab

CSL Behring GmbH

—

ANDEMBRY 200 mg solution for injection in pre-filled syringe EU/1/24/1885/001-002

Garadacimab

CSL Behring GmbH

—

Berinert 1500 IU Powder and solvent for solution for injection PA0800/013/002

C1 Esterase Inhibitor (Human)

CSL Behring GmbH

Not marketed

Berinert 2000 IU Powder and solvent for solution for injection PA0800/013/003

C1 Esterase Inhibitor (Human)

CSL Behring GmbH

Not marketed

Berinert 3000 IU Powder and solvent for solution for injection PA0800/013/004

C1 Esterase Inhibitor (Human)

CSL Behring GmbH

Not marketed

Berinert 500 IU Powder and solvent for solution for injection/infusion. PA0800/013/001

C1 Esterase Inhibitor (Human)

CSL Behring GmbH

Marketed

Beriplex P/N 1000 IU, powder and solvent for solution for injection PA0800/010/003

Factor ii activity, Factor vii activity, Factor x activity, Factor ix activity, Protein c activity

CSL Behring GmbH

Not marketed

Beriplex P/N 250 IU, powder and solvent for solution for injection PA0800/010/001

Factor ii activity, Factor vii activity, Factor x activity, Factor ix activity, Protein c activity

CSL Behring GmbH

Not marketed

Beriplex P/N 500 IU, powder and solvent for solution for injection PA0800/010/002

Factor ii activity, Factor vii activity, Factor x activity, Factor ix activity, Protein c activity

CSL Behring GmbH

Marketed

Hemgenix 1 x 10^13 genome copies/mL concentrate for solution for infusion EU/1/22/1715/001

Etranacogene dezaparvovec

CSL Behring GmbH

—

Hizentra 200 mg/ml solution for subcutaneous injection EU/1/11/687/001-12

Human normal immunoglobulin

CSL Behring GmbH

—

Human Albumin CSL Behring, 200 g/l, solution for infusion PA0800/012/001

Human albumin solution

CSL Behring GmbH

Not marketed

IDELVION 1000 IU powder and solvent for solution for injection EU/1/16/1095/003

Rix-fp

CSL Behring GmbH

—

IDELVION 2000 IU powder and solvent for solution for injection EU/1/16/1095/004

Rix-fp

CSL Behring GmbH

—

IDELVION 250 IU powder and solvent for solution for injection EU/1/16/1095/001

Rix-fp

CSL Behring GmbH

—

IDELVION 3500 IU powder and solvent for solution for injection EU/1/16/1095/009

Albutrepenonacog Alfa

CSL Behring GmbH

—

IDELVION 500 IU powder and solvent for solution for injection EU/1/16/1095/002

Rix-fp

CSL Behring GmbH

—

Privigen 100 mg/ml solution for infusion EU/1/08/446/1-3

Human normal immunoglobulin

CSL Behring GmbH

—

Respreeza 1,000 mg powder and solvent for solution for infusion. EU/1/15/1006/001

Human alpha1-proteinase inhibitor

CSL Behring GmbH

—

Rhophylac 300 micrograms/2 ml, solution for injection in pre-filled syringe PA0800/006/002

Human anti-D immunoglobulin

CSL Behring GmbH

Marketed

Riastap 1 g Powder for Solution for Injection/Infusion PA0800/007/001

Human fibrinogen

CSL Behring GmbH

Not marketed

Tetagam P, prefilled syringeSolution for injection for intramuscular use PA0800/009/002

Human plasma protein

CSL Behring GmbH

Marketed

Voncento 1000 IU/2400 IU Powder and solvent for solution for injection/infusion EU/1/13/857/004

Von willebrand factor, Human coagulation factor viii

CSL Behring GmbH

—

Voncento 250 IU/600 IU Powder and solvent for solution for injection/infusion EU/1/13/857/001

Human coagulation factor viii, Von willebrand factor

CSL Behring GmbH

—

Voncento 500 IU/1200 IU Powder and solvent for solution for injection/infusion EU/1/13/857/002

Von willebrand factor, Human coagulation factor viii

CSL Behring GmbH

—

Voncento 500 IU/1200 IU Powder and solvent for solution for injection/infusion EU/1/13/857/003

Human coagulation factor viii, Von willebrand factor

CSL Behring GmbH

—

Cite this view

Priya Life Science (2026). Irish Medicines Register, filtered. Derived from the HPRA open dataset. Retrieved 3 October 2026. https://priyalifescience.com/medicines/company/csl-behring-gmbh

Download this register

GET /api/export.php?register=medicines-ie&format=csv Try the JSON export →

Regulatory information only — not medical advice. For the authoritative record see the HPRA register directly.